serious adverse events with Gilenya

You'll see new warnings about serious adverse events with Gilenya.

Gilenya (fingolimod) is the first ORAL drug for reducing relapses in patients with relapsing-remitting multiple sclerosis.

But now there are reports of serious cardiac and other problems associated with Gilenya...including 15 deaths outside of Canada.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote